StockTake: First patient joins Tryptamine’s world-first IV psilocin trial for binge-eating disorder

Host Tylah Tully looks at Tryptamine Therapeutics (ASX:TYP), who have enrolled the first patient in its world-first intravenous psilocin trial for Binge Eating Disorder.

The open-label trial will be run in partnership with Swinburne University and plans to test Tryptamine’s IV psilocin therapy TRP-8803, with supportive psychotherapy.

Watch the video to hear the details.

This video was developed in collaboration with Tryptamine Therapeutics, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.